The session drew leaders and experts of many departments ofthe Vietnamese Health Ministry, as well as Xenothera President Odile Duvaux andCEO Bernard Vanhove.
According to the Ministry of Health, XAV-19 is a COVID-19 treatment drug based on polyclonalantibodies that targets COVID-19 patients with moderate conditions.
The first and secondphases of XAV-19 clinical trials’ results showed that the drug is effectiveand safe in preventing the virus to develop, neutralizing the virus andreducing inflammation in patients.
The third phase of XAV-19 clinical trials is being conducted in some Europeancountries.
Odile Duvaux said that her company is willing to cooperatewith Vietnam in implementing the third phase of the trials, and to engage in further discussions on the transfer of the drug production technology toVietnam.
In May this year, the Ministry of Health and Solidarity ofFrance ordered 30,000 doses of XAV-19 from Xenothera.
Deputy Minister Thuan affirmed Vietnam’s readiness to cooperate with Xenotherain implementing the third phase clinical trials of XAV-19 and receivingtechnical transfer from the firm.
Following the working session, a Vietnamese firm discussed with Xenothera specific contents in preparation for the signing of a memorandum of understanding on cooperating inthe third-phase clinical trials of XAV-19 and technology transfer from the French firm./.